2. Search Result
Search Result
Results for "

long lasting effect

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

5

Isotope-Labeled Compounds

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153808A
    Incomplete Freund's adjuvant (IFA)
    4 Publications Verification

    		 Bacterial Inflammation/Immunology Cancer
    Incomplete Freund's adjuvant (IFA) (Montanide ISA-51) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund. Incomplete Freund's adjuvant (IFA) does not contain inactivated tuberculosis bacilli and consists of petroleum jelly containing lanolin. Incomplete Freund's adjuvant (IFA) induces high antibody titers and long-lasting effector T cell responses with no long-term effects on collagen disease, tumors, or death. Complete Freund's adjuvant (CFA) (HY-153808) is another type of Freund's Adjuvant that stimulates a stronger immune response .
    Incomplete Freund's adjuvant (IFA)
  • HY-B0612A
    Lercanidipine hydrochloride
    1 Publications Verification

    		 Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine hydrochloride
  • HY-B0612
    Lercanidipine
    1 Publications Verification

    		 Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine
  • HY-132296
    GSK215
    2 Publications Verification

    		 FAK PROTACs Cancer
    GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .
    GSK215
  • HY-148130
    Rugonersen

    RG6091; RO7248824

    		 E1/E2/E3 Enzyme Others
    Rugonersen (RG6091; RO7248824) is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch .
    Rugonersen
  • HY-107318
    Alacepril

    Cetapril; DU-1219

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Alacepril (Cetapril) is an orally active angiotensin converting enzyme (ACE) inhibitor with long lasting antihypertensive effect .
    Alacepril
  • HY-124701
    Filastatin

    		Fungal Infection
    Filastatin is a long-lasting inhibitor of Candida albicans filamentation. Filastatin inhibits adhesion by multiple pathogenic Candida species with an IC50 of ~3 μM in the GFP-based adhesion assay. Filastatin inhibits fungal adhesion to polystyrene and human cells, the yeast-to-hyphal morphological transition, induction of the hyphal-specific HWP1 promoter. Filastatin has potent antifungal effect .
    Filastatin
  • HY-B0612DS1
    Lercanidipine-d3 hydrochloride

    		Isotope-Labeled Compounds Calcium Channel Cardiovascular Disease
    Lercanidipine-d3 (hydrochloride) is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect .
    Lercanidipine-d3 hydrochloride
  • HY-119832B
    (S)-Setastine

    (S)-EGIS-2062 free acid; (S)-EGYT-2062 free acid

    		 Histamine Receptor Inflammation/Immunology
    (S)-Setastine ((S)-EGIS-2062 free acid) is a non-sedating, highly potent antagonist of H1 receptor-mediated responses. (S)-Setastine has a long-lasting antihistamine effect and good oral efficacy. (S)-Setastine can be used in the research of allergic diseases .
    (S)-Setastine
  • HY-148130A
    Rugonersen sodium

    RG6091 sodium; RO7248824 sodium

    		 E1/E2/E3 Enzyme Others
    Rugonersen sodium is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) sodium is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch .
    Rugonersen sodium
  • HY-143793
    RBP4 inhibitor 1

    		Lipocalin Family Metabolic Disease
    RBP4 inhibitor 1 (compound 43b) is a potent and orally active retinol-binding protein 4 (RBP4) inhibitor with IC50s of 28 nM and 110 nM for human and mouse RBP4. RBP4 inhibitor 1 has a potent and long-lasting blood RBP4-level-reducing effect in mice .
    RBP4 inhibitor 1
  • HY-145552
    Azilsartan mepixetil

    QR-01019

    		 Angiotensin Receptor Cardiovascular Disease
    Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
    Azilsartan mepixetil
  • HY-B0612AS
    Lercanidipine-13C,d3 hydrochloride

    		Calcium Channel Cardiovascular Disease
    Lercanidipine- 13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride . Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect .
    Lercanidipine-13C,d3 hydrochloride
  • HY-130612
    PROTAC BRD2/BRD4 degrader-1

    		Epigenetic Reader Domain PROTACs Cancer
    PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A .
    PROTAC BRD2/BRD4 degrader-1
  • HY-107318R
    Alacepril (Standard)

    Cetapril (Standard); DU-1219 (Standard)

    		 Angiotensin-converting Enzyme (ACE) Reference Standards Cardiovascular Disease
    Alacepril (Standard) is the analytical standard of Alacepril. This product is intended for research and analytical applications. Alacepril (Cetapril) is an orally active angiotensin converting enzyme (ACE) inhibitor with long lasting antihypertensive effect .
    Alacepril (Standard)
  • HY-171758
    BU72

    		Opioid Receptor Neurological Disease
    BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC50 values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence .
    BU72
  • HY-W751579
    Cefovecin

    		Bacterial Antibiotic Infection
    Cefovecin is a third-generation cephalosporin antibiotic. Cefovecin's most notable characteristic is its extremely long-lasting effect; a single subcutaneous injection can maintain an effective therapeutic concentration in tissues for up to 14 days. Cefovecin is used in research on bacterial infections in dogs and cats .
    Cefovecin
  • HY-P991622
    MNAC13

    		Trk Receptor Neurological Disease Inflammation/Immunology
    MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .
    MNAC13
  • HY-B0612AR
    Lercanidipine hydrochloride (Standard)

    		Reference Standards Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB Cardiovascular Disease Neurological Disease
    Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine hydrochloride (Standard)
  • HY-W707863
    Lercanidipine-d3

    		Reactive Oxygen Species (ROS) Neurological Disease
    Lercanidipine-d3 is the deuterium labeled Lercanidipine (HY-B0612). Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .
    Lercanidipine-d3
  • HY-145552A
    Azilsartan mepixetil potassium

    QR-01019K

    		 Angiotensin Receptor Cardiovascular Disease Metabolic Disease
    Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
    Azilsartan mepixetil potassium
  • HY-109023
    Azeloprazole

    		Others Others
    Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H +,K --ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.
    Azeloprazole
  • HY-135427
    Quilostigmine

    HP-290; NXX-066

    		 Drug Derivative Cholinesterase (ChE) Neurological Disease
    Quilostigmine (HP-290) is an orally active Physostigmine (HY-N6608) analogue, acetylcholinesterase (IC50: 148 nM for rat brain acetylcholinesterase) inhibitor. Quilostigmine has a long-lasting effect on tremors. Quetiapine can be used in the research of Alzheimer's disease .
    Quilostigmine
  • HY-B0612AS1
    Lercanidipine-13C,d3-1 hydrochloride

    		Isotope-Labeled Compounds Calcium Channel Cardiovascular Disease
    Lercanidipine- 13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect .
    Lercanidipine-13C,d3-1 hydrochloride
  • HY-145552S
    Azilsartan mepixetil-d5

    QR-01019-d-d5

    		 Isotope-Labeled Compounds Angiotensin Receptor Cardiovascular Disease
    Azilsartan mepixetil-d5 (QR-01019-d5) is deuterium labeled Azilsartan mepixetil. Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
    Azilsartan mepixetil-d5
  • HY-105515
    TJN 220

    		Others Cardiovascular Disease
    TJN 220 is a synthetic derivative of orally active tetrandrine (HY-13764). TJN 220 has a long-lasting and stable antihypertensive effect in various hypertension models. TJN 220 is suitable for controlling nighttime hypertension and does not cause reflex tachycardia. TJN 220 can be used for research on hypertension .
    TJN 220
  • HY-144110
    HCV-IN-37

    		HCV Infection
    HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .
    HCV-IN-37
  • HY-P10203
    μ/κ/δ opioid receptor agonist 1

    		Opioid Receptor Inflammation/Immunology
    μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .
    μ/κ/δ opioid receptor agonist 1
  • HY-165374
    AY-30068

    		Others Inflammation/Immunology
    AY-30068 is an orally effective analgesic. AY-30068 exists in the enterohepatic circulation and has a long-lasting analgesic effect .
    AY-30068
  • HY-124185
    LC 6

    		Others Others
    LC 6 is an anti-allergic compound that has the activity of inhibiting passive cutaneous allergic reactions in rats. Its half effective dose (ED50) is 35 mg/kg body weight. Oral administration is effective and long-lasting, and the effect is obviously dose-dependent. Its long-term binding to mast cells makes it a valuable tool for studying allergic reaction receptors.
    LC 6
  • HY-W748786
    Fenpyrazamine

    		Fungal Infection
    Fenpyrazamine is an antifungal agent. Fenpyrazamine possesses antifungal, preventative, systemic, and lesion-inhibiting activities, as well as a long-lasting effect. Fenpyrazamine targets 3-keto reductase in the ergosterol biosynthesis pathway. Fenpyrazamine is effective against gray mold, stem rot, and brown rot .
    Fenpyrazamine
  • HY-105389
    Tramadol N-oxide

    RWJ-38705

    		 Opioid Receptor Neurological Disease
    Tramadol N-oxide (RWJ 38705) is an analgesic. Tramadol N-oxide sproduces dose-related, long-lasting antinociception. Tramadol N-oxide has affinity for μ opioid receptor (Ki = 38.5 μM) and δ, κ receptors (Ki > 100 μM). Tramadol N-oxide can be used for the study of analgesic effect .
    Tramadol N-oxide
  • HY-185388
    Bupivacaine liposome

    Liposomal bupivacaine

    		 Liposome iGluR Calcium Channel Potassium Channel Sodium Channel Cancer
    Bupivacaine liposome is a liposome-encapsulated form of Bupivacaine (HY-B0405). Bupivacaine is an NMDA receptor inhibitor. During the action potential, Bupivacaine blocks sodium channels, thereby inhibiting the generation and conduction of nerve impulses induced by painful stimuli. Bupivacaine liposome reduces the release rate of Bupivacaine, thus achieving a long-lasting pain relief effect.
    Bupivacaine liposome
  • HY-182503
    GP515

    		Adenosine Kinase Others Inflammation/Immunology
    GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
    GP515
  • HY-P992000
    F8-IL-4

    		Interleukin Related Inflammation/Immunology
    F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis .
    F8-IL-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: